{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T06:52:39Z","timestamp":1790751159723,"version":"4.1.0"},"reference-count":41,"publisher":"MDPI AG","issue":"3","license":[{"start":{"date-parts":[[2023,6,30]],"date-time":"2023-06-30T00:00:00Z","timestamp":1688083200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Medical Sciences"],"abstract":"<jats:p>Von Hippel\u2013Lindau (VHL) loss is the hallmark event characterizing the clear cell renal cancer subtype (ccRCC). Carriers of germinal VHL mutations have an increased prevalence of kidney cysts and ccRCC as well as hemangioblastoma, pheochromocytoma and pancreatic neuroendocrine tumors. In both sporadic and inherited ccRCC, the primary mechanism of VHL-mediated carcinogenesis is the abnormal stabilization of hypoxia-inducible factors (HIF1A and HIF2A). While HIF1A acts as a tumor suppressor and is frequently lost through inactivating mutations\/14q chromosome deletions, HIF2A acts as an oncogene promoting the expression of its target genes (VEGF, PDGF, CAIX Oct4, among others). Selective HIF2a inhibitors block the heterodimerization between HIF2A and ARNT, stopping HIF2A-induced transcription. Several HIF2A inhibitors have entered clinical trials, where they have shown a favorable toxicity profile, characterized by anemia, fatigue and edema and promising activity in heavily pretreated ccRCC patients. Belzutifan, a second-generation HIF2a inhibitor, was the first to receive FDA approval for the treatment of unresectable ccRCC in VHL syndrome. In this review, we recapitulate the rationale for HIF2a blockade in ccRCC, summarize the development of HIF2a inhibitors from preclinical models up to its introduction to the clinic with emphasis on Belzutifan, and discuss their role in VHL disease management.<\/jats:p>","DOI":"10.3390\/medsci11030046","type":"journal-article","created":{"date-parts":[[2023,7,3]],"date-time":"2023-07-03T00:49:27Z","timestamp":1688345367000},"page":"46","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":14,"title":["Selective HIF2A Inhibitors in the Management of Clear Cell Renal Cancer and Von Hippel\u2013Lindau-Disease-Associated Tumors"],"prefix":"10.3390","volume":"11","author":[{"given":"Cristina","family":"Su\u00e1rez","sequence":"first","affiliation":[{"name":"Medical Oncology, Vall d\u2019Hebron Institute of Oncology (VHIO), Vall d\u2019Hebron Barcelona Hospital Campus, Hospital Universitari Vall d\u2019Hebron, 08035 Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7531-343X","authenticated-orcid":false,"given":"Maria","family":"Vieito","sequence":"additional","affiliation":[{"name":"Medical Oncology, Vall d\u2019Hebron Institute of Oncology (VHIO), Vall d\u2019Hebron Barcelona Hospital Campus, Hospital Universitari Vall d\u2019Hebron, 08035 Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Augusto","family":"Valdivia","sequence":"additional","affiliation":[{"name":"Medical Oncology, Vall d\u2019Hebron Institute of Oncology (VHIO), Vall d\u2019Hebron Barcelona Hospital Campus, Hospital Universitari Vall d\u2019Hebron, 08035 Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Macarena","family":"Gonz\u00e1lez","sequence":"additional","affiliation":[{"name":"Medical Oncology, Vall d\u2019Hebron Institute of Oncology (VHIO), Vall d\u2019Hebron Barcelona Hospital Campus, Hospital Universitari Vall d\u2019Hebron, 08035 Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joan","family":"Carles","sequence":"additional","affiliation":[{"name":"Medical Oncology, Vall d\u2019Hebron Institute of Oncology (VHIO), Vall d\u2019Hebron Barcelona Hospital Campus, Hospital Universitari Vall d\u2019Hebron, 08035 Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2023,6,30]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"209","DOI":"10.3322\/caac.21660","article-title":"Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA Cancer J. Clin."},{"key":"ref_2","first-page":"73","article-title":"Metastatic renal cell carcinoma: Update on epidemiology, genetics, and therapeutic modalities","volume":"2","author":"Graves","year":"2013","journal-title":"ImmunoTargets Ther."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"1506","DOI":"10.21037\/tau-20-1150","article-title":"Towards a new WHO classification of renal cell tumor: What the clinician needs to know\u2014A narrative review","volume":"10","author":"Cimadamore","year":"2021","journal-title":"Transl. Androl. Urol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1038\/nature12222","article-title":"Comprehensivemolecular characterization of clear cell renal cell carcinoma","volume":"499","author":"Creighton","year":"2013","journal-title":"Nature"},{"key":"ref_5","doi-asserted-by":"crossref","unstructured":"Razafinjatovo, C., Bihr, S., Mischo, A., Vogl, U., Schmidinger, M., Moch, H., and Schraml, P. (2016). Characterization of VHL missense mutations in sporadic clear cell renal cell carcinoma: Hotspots, affected binding domains, functional impact on pVHL and therapeutic relevance. BMC Cancer, 16.","DOI":"10.1186\/s12885-016-2688-0"},{"key":"ref_6","doi-asserted-by":"crossref","unstructured":"Moore, L.E., Nickerson, M.L., Brennan, P., Toro, J.R., Jaeger, E., Rinsky, J., Han, S.S., Zaridze, D., Matveev, V., and Janout, V. (2011). Von Hippel-Lindau (VHL) inactivation in sporadic clear cell renal cancer: Associations with germline VHL polymorphisms and etiologic risk factors. PLoS Genet., 7.","DOI":"10.1371\/journal.pgen.1002312"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1097\/PAS.0b013e3181ddf54d","article-title":"VHL-gene deletion in single renal tubular epithelial cells and renal tubular cysts: Further evidence for a cyst-dependent progression pathway of clear cell renal carcinoma in von hippel-lindau disease","volume":"34","author":"Montani","year":"2010","journal-title":"Am. J. Surg. Pathol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1038\/ng.2891","article-title":"Genomic architecture and evolution of clear cell renal cell carcinomas defined by multiregion sequencing","volume":"46","author":"Gerlinger","year":"2014","journal-title":"Nat. Genet."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1038\/nrc3844","article-title":"VHL, the story of a tumour suppressor gene","volume":"15","author":"Gossage","year":"2015","journal-title":"Nat. Rev. Cancer"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1016\/j.cmet.2017.10.005","article-title":"Advances in Hypoxia-Inducible Factor Biology","volume":"27","author":"Choudhry","year":"2018","journal-title":"Cell Metab."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"200109","DOI":"10.1098\/rsob.200109","article-title":"The pVHL neglected functions, a tale of hypoxia-dependent and -independent regulations in cancer","volume":"10","author":"Minervini","year":"2020","journal-title":"Open Biol."},{"key":"ref_12","doi-asserted-by":"crossref","unstructured":"Watts, D., Gaete, D., Rodriguez, D., Hoogewijs, D., Rauner, M., Sormendi, S., and Wielockx, B. (2020). Hypoxia pathway proteins are master regulators of erythropoiesis. Int. J. Mol. Sci., 21.","DOI":"10.20944\/preprints202010.0136.v1"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1016\/j.ccr.2008.10.016","article-title":"HIF-\u03b1 Effects on c-Myc Distinguish Two Subtypes of Sporadic VHL-Deficient Clear Cell Renal Carcinoma","volume":"14","author":"Gordan","year":"2008","journal-title":"Cancer Cell"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1158\/2159-8290.CD-11-0098","article-title":"Genetic and functional studies implicate HIF1a as a 14q kidney cancer suppressor gene","volume":"1","author":"Shen","year":"2011","journal-title":"Cancer Discov."},{"key":"ref_15","first-page":"371","article-title":"Prognostic significance of VHL, HIF1A, HIF2A, VEGFA and p53 expression in patients with clear-cell renal cell carcinoma treated with sunitinib as first-line treatment","volume":"55","author":"Wierzbicki","year":"2019","journal-title":"Int. J. Oncol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"214","DOI":"10.3389\/fonc.2018.00214","article-title":"Hypoxia-inducible factor 2-dependent pathways driving Von Hippel-Lindau-deficient renal cancer","volume":"8","author":"Roche","year":"2018","journal-title":"Front. Oncol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"1","DOI":"10.15586\/jkcvhl.v8i2.170","article-title":"Hypoxia-Inducible Factor-2\u03b1 as a Novel Target in Renal Cell Carcinoma","volume":"8","author":"Choi","year":"2021","journal-title":"J. Kidney Cancer VHL"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1038\/nchembio.1185","article-title":"Allosteric inhibition of hypoxia inducible factor-2 with small molecules","volume":"9","author":"Scheuermann","year":"2013","journal-title":"Nat. Chem. Biol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1038\/nature19796","article-title":"Targeting renal cell carcinoma with a HIF-2 antagonist","volume":"539","author":"Chen","year":"2016","journal-title":"Nature"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"5491","DOI":"10.1158\/0008-5472.CAN-16-0473","article-title":"A small-molecule antagonist of HIF2\u03b1 is efficacious in preclinical models of renal cell carcinoma","volume":"76","author":"Wallace","year":"2016","journal-title":"Cancer Res."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1016\/S1470-2045(23)00097-9","article-title":"Belzutifan plus cabozantinib for patients with advanced clear cell renal cell carcinoma previously treated with immunotherapy: An open-label, single-arm, phase 2 study","volume":"24","author":"Choueiri","year":"2023","journal-title":"Lancet Oncol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"6330","DOI":"10.1158\/1538-7445.AM2022-6330","article-title":"Abstract 6330: NKT2152: A highly potent HIF2\u03b1 inhibitor and its therapeutic potential in solid tumors beyond ccRCC","volume":"82","author":"Lu","year":"2022","journal-title":"Cancer Res."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"5669","DOI":"10.2147\/OTT.S190753","article-title":"Von hippel-lindau disease: Current challenges and future prospects","volume":"13","author":"Vergauwen","year":"2020","journal-title":"OncoTargets Ther."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1111\/j.1755-3768.1926.tb07786.x","article-title":"Zur Frage der Angiomatosis retinae und ihrer Hirnkomplikationen","volume":"4","author":"Lindau","year":"1926","journal-title":"Acta Ophthalmol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1007\/BF01994821","article-title":"\u00dcber eine sehr seltene Erkrankung der Netzhaut: Klinische Beobachtungen","volume":"59","author":"Hippel","year":"1904","journal-title":"Albrecht Graefes Arch. Ophthalmol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"20","DOI":"10.15586\/jkcvhl.2017.88","article-title":"A Review of Von Hippel-Lindau Syndrome","volume":"4","author":"Varshney","year":"2017","journal-title":"J. Kidney Cancer VHL"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1136\/jnnp.67.6.758","article-title":"The impact of molecular genetic analysis of the VHL gene in patients with haemangioblastomas of the central nervous system","volume":"67","author":"Bender","year":"1999","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"833","DOI":"10.2174\/1566524043359827","article-title":"Von Hippel-Lindau disease","volume":"4","author":"Maher","year":"2004","journal-title":"Curr. Mol. Med."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/j.clgc.2017.07.027","article-title":"Radiofrequency Ablation for Renal Cancer in Von Hippel\u2013Lindau Syndrome Patients: A Prospective Cohort Analysis","volume":"16","author":"Allasia","year":"2018","journal-title":"Clin. Genitourin. Cancer"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1007\/s10689-012-9525-7","article-title":"Nephron sparing surgery in von Hippel-Lindau associated renal cell carcinoma; Clinicopathological long-term follow-up","volume":"11","author":"Jilg","year":"2012","journal-title":"Fam. Cancer"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"2661","DOI":"10.1093\/annonc\/mdr011","article-title":"Pilot trial of sunitinib therapy in patients with von Hippel\u2013Lindau disease","volume":"22","author":"Jonasch","year":"2011","journal-title":"Ann. Oncol."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"85306","DOI":"10.18632\/oncotarget.13301","article-title":"Sunitinib for the treatment of benign and malignant neoplasms from von Hippel-Lindau disease: A single-arm, prospective phase II clinical study from the PREDIR group","volume":"7","author":"Oudard","year":"2016","journal-title":"Oncotarget"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"1351","DOI":"10.1016\/S1470-2045(18)30487-X","article-title":"Pazopanib in patients with von Hippel-Lindau disease: A single-arm, single-centre, phase 2 trial","volume":"19","author":"Jonasch","year":"2018","journal-title":"Lancet Oncol."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1200\/JCO.2017.74.2627","article-title":"Phase I dose-escalation trial of PT2385, a first-in-class hypoxia-inducible factor-2a antagonist in patients with previously treated advanced clear cell renal cell carcinoma","volume":"36","author":"Courtney","year":"2018","journal-title":"J. Clin. Oncol."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1200\/JCO.2019.37.7_suppl.558","article-title":"Results from a phase I expansion cohort of the first-in-class oral HIF-2\u03b1 inhibitor PT2385 in combination with nivolumab in patients with previously treated advanced RCC","volume":"37","author":"Rini","year":"2019","journal-title":"J. Clin. Oncol."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"4509","DOI":"10.1200\/JCO.2022.40.16_suppl.4509","article-title":"Phase 1 LITESPARK-001 (MK-6482-001) study of belzutifan in advanced solid tumors: Update of the clear cell renal cell carcinoma (ccRCC) cohort with more than 3 years of total follow-up","volume":"40","author":"Jonasch","year":"2022","journal-title":"J. Clin. Oncol."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"2036","DOI":"10.1056\/NEJMoa2103425","article-title":"Belzutifan for Renal Cell Carcinoma in von Hippel\u2013Lindau Disease","volume":"385","author":"Jonasch","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"1423","DOI":"10.1164\/rccm.201710-2079OC","article-title":"Therapeutic targeting of vascular remodeling and right heart failure in pulmonary arterial hypertension with a HIF-2a inhibitor","volume":"198","author":"Dai","year":"2018","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"4546","DOI":"10.1200\/JCO.2022.40.16_suppl.4546","article-title":"LITESPARK-004 (MK-6482-004) phase 2 study of belzutifan, an oral hypoxia-inducible factor 2\u03b1 inhibitor (HIF-2\u03b1), for von Hippel-Lindau (VHL) disease: Update with more than two years of follow-up data","volume":"40","author":"Jonasch","year":"2022","journal-title":"J. Clin. Oncol."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"2027","DOI":"10.1200\/JCO.2019.37.15_suppl.2027","article-title":"Safety and activity of a first-in-class oral HIF2-alpha inhibitor, PT2385, in patients with first recurrent glioblastoma (GBM)","volume":"37","author":"Strowd","year":"2019","journal-title":"J. Clin. Oncol."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"S681","DOI":"10.1016\/j.annonc.2021.08.052","article-title":"656MO Phase II study of belzutifan (MK-6482), an oral hypoxia-inducible factor 2\u03b1 (HIF-2\u03b1) inhibitor, plus cabozantinib for treatment of advanced clear cell renal cell carcinoma (ccRCC)","volume":"32","author":"McDermott","year":"2021","journal-title":"Ann. Oncol."}],"container-title":["Medical Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2076-3271\/11\/3\/46\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T20:04:16Z","timestamp":1760126656000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2076-3271\/11\/3\/46"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,6,30]]},"references-count":41,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2023,9]]}},"alternative-id":["medsci11030046"],"URL":"https:\/\/doi.org\/10.3390\/medsci11030046","relation":{},"ISSN":["2076-3271"],"issn-type":[{"value":"2076-3271","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,6,30]]}}}